Research demonstrates hydrogen-mediated therapy improves psoriasis remission and reduces relapse in chronic conditions, indicating a novel treatment approach.
Psoriasis represents a globally prevalent and chronic dermatological disorder, characterized by persistent hyperkeratosis, self-sustaining inflammatory cycles, and frequent relapse, posing substantial challenges for conventional therapies of compromised efficacy and biosafety. Here, we introduce a transformative strategy of hydrogen-mediated topical psoriasis therapy based on the construction of an in-situ formed, microbubble hydrogel that facilitates significant H 2 generation and subsequently prolonged delivery. By fabricating and incorporating MgH 2 nanoparticles into an amphiphilic, thermosensitive hydrogel via self-assembly in saline, the hydrogen evolution reaction, generated microbubble morphology and storage can be well controlled, reaching optimized H 2 release profile at saturated concentration (∼0.8 mM) over days. We demonstrate marked alleviation of psoriasis-like pathologies with this local hydrogen treatment in vitro and in vivo , revealing superior efficacy compared to both Imiquimod-induced mice model and clinical Calcipotriol drug. Mechanistically, we disclose continuous hydrogenation directly suppresses psoriatic keratinocyte hyperproliferation via anti-Warburg effect and energy metabolic reprogramming through the PKM2-mediated pathway, and meanwhile coordinating redox homeostasis restoration which further disrupts the inflammation-immune feedback loop. We also identify the potency of this H 2 -regulated energy metabolism strategy in preventing psoriasis recurrence. Collectively, this work delivers a proof-of-concept of hydrogen-mediated psoriasis energy therapy (HPET) with translatable promise for potentiating long-term management. • Engineered hydrogenated microbubble gel enables local, adequate, and durable H 2 release. • Mechanistic insights reveal H 2 selectively downregulates keratinocyte energy metabolism. • Topical hydrogen-mediated psoriasis energy therapy (HPET) mitigatesits onset and recurrence with high biocompatibility.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: